home / stock / regn / regn news

REGN News and Press, Regeneron Pharmaceuticals Inc. From 04/22/24

Stock Information
Company Name: Regeneron Pharmaceuticals Inc.
Stock Symbol: REGN
Market: NASDAQ
Website: regeneron.com
Menu
REGN REGN Quote REGN Short REGN News REGN Articles REGN Message Board
Get REGN Alerts

News, Short Squeeze, Breakout and More Instantly...
REGN - Additions and deletions of Oppenheimer's OPCO Trifecta

2024-04-22 15:42:04 ET More on United States 10-Year Bond Yield: Wall Street Lunch: Bond Bulls In Hibernation Dollar Consolidates But Adjustment Is Not Over Wall Street Lunch: So Long Summer Of Rate Cuts Bond yields tick down as cash moves to safety following...
REGN - Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN ). The investigation concerns whether Regeneron and/or certai...

REGN - Regeneron to "vigorously defend" against DOJ on Eylea pricing complaint

2024-04-16 08:37:08 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

REGN - Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain add...
REGN - Buy Recommendation Issued On REGN By Truist Financial

2024-04-12 12:15:02 ET Truist Financial analyst issues BUY recommendation for REGN on April 12, 2024 10:01AM ET. The previous analyst recommendation was Buy. REGN was trading at $903.175 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

REGN - Stocks with the least price swings, most attractive option-sale candidates - JPM

2024-04-12 10:44:43 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Solid Track Record, But Looks Overextended Now 10 Attractive sell puts within the Russell 1000 - JPM 10 Attractive buy puts within the Russell 1000 - JPM Seeking Alpha’s Quant Rat...

REGN - DOJ files complaint against Regeneron over Eylea Medicare pricing

2024-04-11 08:55:34 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...
REGN - DOJ sues Regeneron over Eylea Medicare pricing

2024-04-10 17:09:55 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

REGN - Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) a...

REGN - Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst

2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...
Previous 10 Next 10